Avidity Partners Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.38M | Sell |
107,891
-121,109
| -53% | -$3.79M | 0.67% | 39 |
|
|
2025
Q1 | $7.68M | Sell |
229,000
-245,000
| -52% | -$8.22M | 1.46% | 23 |
|
|
2024
Q4 | $18.6M | Sell |
474,000
-344,000
| -42% | -$13.5M | 1.82% | 24 |
|
|
2024
Q3 | $32.2M | Buy |
818,000
+64,000
| +8% | +$2.52M | 1.64% | 25 |
|
|
2024
Q2 | $29.4M | Buy |
754,000
+44,000
| +6% | +$1.72M | 1.25% | 31 |
|
|
2024
Q1 | $30.6M | Sell |
710,000
-105,993
| -13% | -$4.56M | 0.99% | 34 |
|
|
2023
Q4 | $37.6M | Buy |
815,993
+494,593
| +154% | +$22.8M | 1.37% | 33 |
|
|
2023
Q3 | $11M | Sell |
321,400
-159,900
| -33% | -$5.46M | 0.44% | 66 |
|
|
2023
Q2 | $18.5M | Buy |
+481,300
| New | +$18.5M | 0.65% | 55 |
|
|
2022
Q3 | – | Sell |
-450,000
| Closed | -$13.7M | – | 107 |
|
|
2022
Q2 | $13.7M | Buy |
+450,000
| New | +$13.7M | 0.31% | 46 |
|